GlassScriptPhysician profile
Kenneth T Ashkin
NPI 1306896592
$9,499.79
in general payments reported to CMS, 2019-2025
44 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $1,054 · 2021: $1,309 · 2022: $1,468 · 2023: $1,340 · 2024: $1,869 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,684 · Education: $25.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,683.61 |
| Education | $25.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,102.40 | 2019-2025 | |
| Neurelis, INC. | $1,034.56 | 2022-2025 | Valtoco |
| Ucb, INC. | $941.19 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Takeda Pharmaceuticals U.S.A., INC. | $579.27 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $510.61 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $493.41 | 2020-2025 | Wakix |
| Neos Therapeutics, LP | $474.57 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $413.63 | 2019-2024 | Jornay Pm |
| Greenwich Biosciences, INC. | $369.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $307.22 | 2020-2023 | Belsomra |
| Tris Pharma INC | $295.48 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $257.75 | 2022-2025 | Sunosi |
| Sk Life Science, INC. | $228.48 | 2020-2023 | |
| Corium, LLC | $216.61 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $199.19 | 2019-2022 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ashkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.